1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CStone Pharmaceuticals
  6. News
  7. All News
    2616   KYG2588M1006

CSTONE PHARMACEUTICALS

(2616)
  Report
Delayed Hong Kong Stock Exchange  -  03/31 04:08:07 am EDT
5.040 HKD   -9.84%
05/17CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interim
AQ
05/16CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemalimab in Patients with Stage III NSCLC
CI
04/28CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about CSTONE PHARMACEUTICALS
05/17CStone announces final PFS analysis of a registrational study of sugemalimab in patient..
AQ
05/16CStone Pharmaceuticals Announces Final PFS Analysis of Registrational Study of Sugemali..
CI
04/28CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and an..
AQ
04/22CStone Announces Results From Phase 3 AGILE Data of TIBSOVO
AQ
04/21CStone Pharmaceuticals Announces Publication of Results from the Phase 3 Agile Trial of..
CI
04/13CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Th..
AQ
04/12CStone Pharma Presents Immunotherapy Candidate's Preclinical Data at US Oncology Confer..
MT
04/12CStone Pharmaceuticals Announces Presentation of Preclinical Data on A Multi-Specific A..
CI
03/31CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of ..
AQ
03/30CStone Pharmaceuticals Announces First Patient Enrollment in the U.S. in the Phase 1 Cl..
CI
03/18CStone announced the global multi-regional registration trial of anti-PD-1 antibody nof..
AQ
03/17CStone Pharmaceuticals Announces the Acceptance of New Drug Application for Pralsetinib..
CI
03/17Cstone Pharmaceuticals Announces Global Multi-Regional Registration Trial of Anti-PD-1 ..
CI
03/16CStone's partner Servier announces significant developments for TIBSOVO (ivosidenib tab..
AQ
03/14CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanc..
AQ
03/13China OKs CStone Pharma's Supplemental NDA for Cancer Treatment; Shares Slide 5%
MT
03/13CStone Pharmaceuticals Announces the NMPA Approval of GAVRETO (pralsetinib) for the Tre..
CI
02/16Taiwan Accepts CStone's New Drug Application for Lung, Thyroid Cancer Therapy
MT
02/16CStone Pharmaceuticals Announces the Acceptance of New Drug Application for Pralsetinib..
CI
02/09CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO (ivosidenib ..
AQ
02/08CStone Pharmaceuticals Announced New Drug Approval of China's First Idh1 Inhibitor Tibs..
CI
01/19CStone announced two key phase 3 registrational clinical trials of sugemalimab complete..
AQ
01/19EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically S..
CI
01/18CStone Pharma Says Lung Cancer Treatment Improves Overall Survival of Patients in Clini..
MT
01/18CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall surv..
PR
01/18CStone Pharmaceuticals Announces Gemstone-302 Study of Sugemalimab Met the Endpoint of ..
CI
01/17CStone Pharma Completes Patient Enrollment for Two Key Studies of Cancer Drug; Shares J..
MT
01/17CStone Pharmaceuticals Announces Two Key Phase 3 Registrational Clinical Trials of Suge..
CI
01/16CStone Pharma's Lung Cancer Treatment Featured in Medical Journal
MT
01/14CStone Pharmaceuticals Announces the Clinical Data from Registrational Study of Sugemal..
CI
01/14Cstone Pharmaceuticals Announces the Registrational Clinical Study Results of Sugemalim..
CI
01/12CStone Pharma's Investigational Antibody Boosts Objective Response Rate of Lymphoma Pat..
MT
01/12CStone Announces Phase 2 GEMSTONE-201 Trial Met Primary Endpoint of Objective Response ..
CI
01/04CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in..
AQ
01/04CStone Pharma Gets Nod to Start China Study of Therapy for ROS1-Positive Lung Cancer
MT
01/04CStone Announces IND Approval for the Pivotal Study in China of Lorlatinib for the Trea..
CI
01/03CStone Pharma Gets FDA Nod to Begin US Clinical Trial of Therapy Targeting ROR1 Cancer ..
MT
01/03CStone Pharmaceuticals Announces the IND Approval of CS5001, a Potential Global Best-In..
CI
2021CStone Pharmaceuticals announced new drug approval for precision therapy AYVAKIT (avapr..
AQ
2021CStone Pharmaceuticals Unaware of Unusual Share Price and Trading Volume Movements
MT
2021Hong Kong Approves CStone Pharma's Precision Therapy for Gastrointestinal Stromal Tumor
MT
2021CStone Announces New Drug Approval of Precision Therapy AYVAKIT« (Avapritinib) in Hong ..
CI
2021Ligand's partner cstone pharmaceuticals receives approval in china for sugemalimab (cej..
AQ
2021Ligand Pharmaceuticals' Partner Gets Approval for Lung Cancer Drug in China
MT
2021CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly«) for the Fi..
CI
2021China Approves CStone Pharma Drug for Stage IV Lung Cancer Treatment
MT
2021Cstone announced new drug approval of cejemly« (sugemalimab) in china to potentially re..
AQ
2021CStone Pharmaceuticals Announces New Drug Approval of Cejemly (Sugemalimab) in China to..
CI
2021Transcenta Hires Former CStone Pharma Exec as CFO
MT
2021CStone Pharmaceuticals - Phase 3 Data Show That TIBSOVO in Combination with Azacitidine..
AQ
2021CStone Pharmaceuticals' Leukemia Drug, Chemotherapy Improves Patient Survival in Phase ..
MT
2021Cstone Pharmaceuticals Announces Executive Changes
CI
2021CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater C..
MT
2021CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnersh..
AQ
2021Cstone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals Announce Strategic Partnersh..
CI
2021CStone Pharma Strikes Antibody Therapy Collaboration Deal with Singapore's DotBio
MT
2021CStone Pharmaceuticals and DotBio Pte. Ltd enter into a collaboration agreement
CI
2021CStone's partner, Servier, will present the first Phase 3 results from the global AGILE..
AQ
2021CStone Pharmaceuticals Received China NMPA IND Acceptance for lorlatinib in Chinese Pat..
CI
2021CSTONE PHARMACEUTICALS : Chinese Regulators OK CStone's Investigational New Drug Applicati..
MT
2021CSTONE PHARMACEUTICALS : presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-..
AQ
2021CSTONE PHARMACEUTICALS : Achieves Potential Antitumor Activity From Preclinical Antibody T..
MT
2021CStone Presents Arrow Study Data for GAVRETO? (Pralsetinib) in Chinese Patients with Re..
CI
2021CSTONE PHARMACEUTICALS : announced that the research data of CS5001 (ROR1 ADC) has been se..
AQ
2021CSTONE PHARMACEUTICALS : Pharma Presents Cancer Drug's Bridging Study Data at Oncology Con..
MT
2021CSTONE PHARMACEUTICALS : presents preliminary results from a phase Ib study of the anti-CT..
AQ
2021CStone Pharmaceuticals Presents Clinical Data from the China Registrational Bridging St..
CI
2021CSTONE PHARMACEUTICALS' : Investigational Cancer Treatment Shows Potential in Phase 1b Tri..
MT
2021Cstone Presents Preliminary Results from Phase Ib Study of the Anti-Ctla-4 Monoclonal A..
CI
2021EQRx and its Partner CStone Pharmaceuticals Announce Presentation of Phase 3 Data Demon..
CI
2021CStone Pharmaceuticals Will Present Registrational Clinical Study Data of Sugemalimab i..
CI
2021CSTONE PHARMACEUTICALS : to Present Phase 3 Trial Data of Non-Small Cell Lung Cancer Treat..
MT
2021CSTONE PHARMACEUTICALS : received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-..
AQ
2021CSTONE PHARMACEUTICALS : Wins Chinese Regulators' OK to Start Clinical Trial of Advanced S..
MT
2021CStone Pharmaceuticals Receives China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4..
CI
1  2  3  4Next
Upcoming event on CSTONE PHARMACEUTICALS